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Background: Data sources for MS research are numerous but rarely provide an objective measure of drug therapy
compliance coupled with patient-reported health outcomes. The objective of this paper is to describe the methods
and baseline characteristics of the Therapy Optimization in MS (TOP MS) study designed to investigate the
relationship between disease-modifying therapy compliance and health outcomes.
Methods: TOP MS was designed as a prospective, observational, nationwide patient-focused study using an
internet portal for data entry. The protocol was reviewed and approved by Sterling IRB. The study was registered
with ClinicalTrials.gov. It captured structured survey data monthly from MS patients recruited by specialty
pharmacies. Data collection included the clinical characteristics of MS such as MS relapses. Disability, quality of life
and work productivity and activity impairment were assessed quarterly with well-validated scales. When events like
severe fatigue or new or worsening depression were reported, feedback was provided to treating physicians. The
therapy compliance measure was derived from pharmacy drug shipment records uploaded to the study database.
The data presented in this paper use descriptive statistics.
Results: The TOP MS Study enrolled 2966 participants receiving their disease-modifying therapy (DMT) from
specialty pharmacies. The mean age of the sample was 49 years, 80.4% were female, 89.9% were Caucasian and
55.7% were employed full or part time. Mean time since first symptoms was 11.5 years; mean duration since
diagnosis was 9.5 years. Patient-reported EDSS was 3.5; 72.2% had a relapsing-remitting disease course. The most
commonly reported symptoms at the time of enrollment were fatigue (74.7%), impaired coordination or balance
(61.8%) and numbness and tingling (61.2%). Half of the sample was using glatiramer acetate and half was using
beta-interferons.
Conclusion: Demographic and clinical characteristics of the TOP MS sample at enrollment are consistent with other
community-based MS samples, and the sample appears to be representative of DMT users in the US. TOP MS data
can be used to explore the associations between disease-modifying therapy compliance and health outcomes.
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Multiple Sclerosis (MS) is one of the most common
diseases of the central nervous system [1]. The socio-
economic burden of MS begins with the onset of symp-
toms most typically in the third and fourth decade of
life and extends over many years. Although there is no
cure for MS, the disease-modifying therapies (DMTs) have
been shown to reduce relapses and slow the progression
of disability [1-3].
A core issue for treatment of MS is medication com-
pliance, defined as the extent to which a patient acts in
accordance with the prescribed interval and dose of a
dosing regimen [4]. Drug compliance is important to en-
sure patients receive the maximum benefit from their
treatment and minimize worsening of their disease.
Examining the relationship between DMT compliance
and health outcomes in MS was the rationale for design-
ing and implementing the Therapy Optimization in Mul-
tiple Sclerosis (TOP MS) study.
Several data sources have been used to examine health
outcomes in MS [5-8]. The NARCOMS Registry consists
of a large database of MS patients who are followed semi-
annually with self-administered questionnaires including
validated patient-reported outcome measures [5]. The
New York State MS Consortium Registry offers physician-
reported outcomes for its participants [6]. Both data
sources rely on patient self-reports about DMT compliance
[5,6]. Databases of healthcare claims from managed care
plans or a claims database from a Pharmacy Benefit
Management company with a specialty component offer
prescription claims for estimates of drug therapy compli-
ance and a reliable algorithm-based MS relapse measure,
but they contain no data on disability, duration of disease,
or quality of life [7-9].
To meet the needs of the TOP MS study for both drug
compliance and MS health outcomes, US specialty
pharmacies that provide DMTs for MS patients were
invited to assist with study recruitment. Web-based surveys
to capture health outcomes would supplement their
medication therapy management (MTM) programs for
MS designed to optimize treatment [10]. The pharmacies
were willing to provide DMT shipment information to the
TOP MS study database that could be used to calculate
the compliance measure they most commonly use, the
Medication Possession Ratio (MPR) [4,11].
The objectives of this report are to describe the methods
and baseline characteristics of the TOP MS study.
Methods
The TOP MS study used a prospective, open-label parallel
group study design involving approximately 3000 persons
with MS who were receiving immunomodulatory ther-
apy from one of three specialty pharmacies: Diplomat
Specialty Pharmacy, BioScrip Inc., and Walgreens SpecialtyPharmacy. The objective of TOP MS was to determine
the association of varying levels of compliance with MS
therapy on patient outcomes. The study was sponsored
and conducted by Teva Pharmaceuticals, Inc, with
oversight by the TOP MS Study Steering Committee, a
group of neurologists who specialize in the treatment
and management of MS.
Inclusion criteria for TOP MS included males and
females, 18 years of age or older, with a diagnosis of
MS, who were continuing or initiating treatment with
approved doses of glatiramer acetate (GA, Copaxone,
Teva Pharmaceuticals, Inc.), intramuscular or subcutaneous
interferon beta-1a (IFNβ-1a IM; Avonex, Biogen Idec;
IFNβ-1a SC, Rebif, EMD-Serono), or interferon beta-1b
(IFNβ-1b, Betaseron, Bayer Pharmaceuticals, Inc.). No
restrictions were placed on the number of enrolled patients
using each of the DMTs.
Exclusion criteria were limited to contraindications
to the immunomodulators (including pregnancy, trying
to become pregnant or breastfeeding), and any condi-
tion that might interfere with participation for the full
24-month duration of the study.
There were no disallowed previous medications.
Concomitant medications could include any treatments for
MS except investigational drugs. Any concomitant diseases
were allowed and recorded.
The study protocol was reviewed and approved by
Sterling IRB. The TOP MS study was registered with
ClinicalTrials.gov (NCT00819000).
MedNet Solutions, a database development company,
was contracted to build a research-quality database that
could capture the patient-reported data for the study.
MedNet also hosted the web portal.
Before beginning study procedures, pharmacy study
managers received training from the study sponsor on
MS and study procedures. Thereafter, they participated
in weekly teleconferences to discuss study issues.
Prior to study enrollment, treating physicians with
potential participants from each specialty pharmacy re-
ceived an informational brochure or letter about the
TOP MS study. They were invited to receive biannual
participant-specific reports during the study suitable for
inclusion in the patients’ charts.
When patient recruitment began, study managers
called potential participants to introduce the TOP MS
study. If patients agreed to receive additional informa-
tion, IRB-approved informed consent forms (ICF) out-
lining the procedures and evaluations for the study
were mailed. Signed ICF were returned to the pharma-
cies, and study managers initiated study enrollments
through the web-based portal. Demographic charac-
teristics for all potential participants and the enrolled
sample were available from the pharmacies and are
presented in Table 1.
Table 1 Characteristics of persons contacted, excluded, lost, and enrolled
Characteristic Contacted, no response Refused participation Enrolled, lost before baseline Enrolled successfully
(n = 6766)
n%
(n = 3710)
n%
(n = 185)
n%
(n = 2966)
n%
Age (Years)
≤ 30 536 ( 7.9) 164 ( 4.4) 7 ( 3.8) 140 ( 4.7)
31 – 40 1434 (21.2) 517 (13.9) 30 (16.3) 455 (15.3)
41 – 50 2207 (32.6) 1000 (27.0) 54 (29.2) 885 (29.8)
51 – 60 1873 (27.7) 1291 (34.8) 65 (34.9) 1068 (36.0)
≥ 61 716 (10.6) 738 (19.9) 29 (15.8) 418 (14.1)
Gender
Female 5200 (76.9) 2815 (75.9) 153 (82.8) 2385 (80.4)
Male 1566 (23.1) 895 (24.1) 32 (17.2) 581 (19.6)
Dispensed DMT:
GA 3187 (47.1) 1677 (45.2) 99 (53.6) 1475 (49.7)
IFNβ-1a IM 1504 (22.2) 857 (23.1) 30 (16.3) 604 (20.4)
IFNβ-1a SC 1172 (17.3) 678 (18.3) 29 (15.8) 470 (15.8)
IFNβ-1b 903 (13.3) 498 (13.4) 27 (14.4) 417 (14.1)
DMT, Disease-modifying therapy; IFNβ-1a IM, Intramuscular interferon beta-1a; IFNβ-1b, Interferon beta -1b; GA, Glatiramer acetate; IFNβ-1a SC, Subcutaneous
interferon beta-1a.
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instructions for the portal. A link to technical support
was also available. Beginning at baseline and at regular
intervals over 24 months, enrolled participants received
electronic messages to respond to survey questions within
two-week windows. Near the end of the windows tele-
phone reminders were initiated. Self-reported responses
were entered directly into the study database and stored
for later analyses. Those who changed or stopped DMT
and were willing to continue to provide responses to ques-
tionnaires were allowed to remain in the study. If three
consecutive months of surveys were missed, and partici-
pants could not be reached by telephone, they were con-
sidered to have discontinued the study.
The therapy compliance measure, MPR, was derived
from pharmacy shipment records. MPR was defined as
the ratio of days that the patient had drug to take at
the prescribed frequency to the number of days in the
interval (i.e., 12 months), expressed as a decimal or
percentage [11,12].
Data collection
Study questionnaires for the clinical characteristics of MS
were designed by the TOP MS Study Steering Committee
and included MS history, comorbidities, MS therapy
history, relapses (history and presence at baseline), and
targeted adverse events. Table 2 presents the modules
captured at each study time point.
Disability was assessed with the validated Self-Assessed
Kurtzke developed by Dr. L.C. Scheinberg. A self-
report disability rating scale, the responses are highlycorrelated with scores on the Expanded Disability Status
Scale (EDSS) [13].
Health-related quality of life was assessed with the
validated Short Form Health Survey, 12 items, version 2
(SF-12v.2®) that generates Physical and Mental Component
Scores [14]. Our database was designed to allow completed
SF-12v.2 forms to be scored by QualityMetric, the scale
developer. They submitted scores directly to the TOP MS
Study database.
For those employed full or part time, the validated Work
Productivity and Activity Impairment: General Health
(WPAI:GH) scale was used to assess lost work time
due to MS and the impact of MS on completing tasks
while at work [15]. All participants completed the scale
question concerning the interference of MS with doing
usual daily activities other than employment.
Covariates used in the study included MS disease type,
disease duration, demographic characteristics, comorbidi-
ties, fatigue, depression and cognitive deficits.
MS disease type was determined from responses to spe-
cific questions on the TOP MS survey dealing with relapse
history, onset of initial symptoms, and subject assessment
of their MS relative to six months prior used as a proxy
for progression. Disease duration was measured 1) from
time of first symptoms that the physician attributed to MS
and 2) from date of diagnosis.
Comorbidities were queried at baseline and updated
every three months. Fatigue severity was assessed with the
validated 9-item Fatigue Severity Scale (FSS) every three
months [16]. The Patient Health Questionnaire (PHQ-9)
was used to screen for depression (first two questions),
Table 2 Data collection by time points
Modules Baseline Months 1,2,4,5,7,8,
10,11,13,14
16,17,19,20,
22,23
Months
3,9,15,21
Months
6, & 18
Months
12 & 24
Demographic characteristics X
Co-morbidities baseline/updates X X X X
MS history X
MS therapies & concomitant drug history/updates X X X X
Relapses, history and current X
Current DMT X X X X
Current MS status (relapse) Xf Xf Xf X
Targeted eventsa X X X X X
Quality of Life (SF-12v.2™) X X X X
Disability: Self-Assessed Kurtzke X X X
Fatigue Severity Scale (FSS) X X X X
Patient Health Questionnaire (PHQ-9)b X X X X
Perceived Deficits Questionnaire (PDQ-5)c X X X
Work Productivity and Activity Impairment: General Health (WPAI:GH) X X X X
Drug shipment data for compliance & persistenced X X X X X
Terminatione X
24 months
DMT, Disease-modifying therapy; SF-12v.2™, Short Form Health Survey, 12 items, version 2, [14].
aMost commonly reported adverse events; Includes reports of pregnancy; bDepression screener/severity assessment [17,18]; cCognition screener [19]; dShipment
data were uploaded electronically to study database; eTermination module was asked when a patient left the study or completed follow-up. fAt report of relapse,
Self-Assessed Kurtzke was completed and repeated in six months [13].
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verity [17,18]. Cognitive deficits were assessed every
six months with the validated 5-item Perceived Deficits
Questionnaire (PDQ-5) developed specifically for MS
patients [19]. The study included faxed or mailed follow-
up with treating physicians when events such as severe
fatigue or new depression or worsening depression
were reported.
Safety assessment in the TOP MS Study included
monthly queries about commonly reported adverse events
associated with the study DMTs. Serious Adverse Events
(SAEs) meeting the criteria of seriousness for regula-
tory requirements were reviewed by the study Medical
Monitor for relatedness to study DMTs and submitted to
manufacturers’ Pharmacovigilance departments. Reported
pregnancies were also tracked.
Data analysis
After data collection was completed, the biostatistician
extracted the study data from the study website database
server, and the data were analyzed using “R” software,
version 3.0.0 or higher (The R Foundation for Statistical
Computing, Vienna, Austria). Data for each module
were maintained in separate data structures, linked by
unique participant identifiers. At no time during thestudy did the study sponsor have access to patient names
or contact information.
In this report, we present frequency distributions for
selected variables from the baseline survey modules.
Results
Evaluating representativeness
The enrolled TOP MS sample (n = 2966) was evaluated
for representativeness relative to those who were con-
tacted about participation but did not respond (n = 6766),
those who refused to participate (n = 3710), and those
who enrolled but did not complete the baseline survey
and were lost from the study (n = 185). We present the
comparative data in Table 1 as benchmarks. While the
enrolled sample was somewhat more likely to be female,
more likely to be 51 to 60 years old and less likely to be
40 years or younger, the distribution of DMT use was
similar to the full sample of potential participants. There
was nationwide representation with participants and non-
participants from all fifty states, District of Columbia and
Puerto Rico.
Demographic characteristics at baseline
Table 3 describes the demographic characteristics of the
enrolled TOP MS sample.
Table 3 Baseline demographic characteristics of prevalent
MS patients
Characteristic Mean SD
Age (Years) 49.0 10.3
Characteristic n %
Race:
Caucasian 2666 89.9
Black/African American 172 5.8
Hispanic/Latino 68 2.3
Mixed race 31 1.0
Other races 29 1.0
Gender: Female 2385 80.4
Employment status:
Employed, full time 1294 43.6
Employed, part time 290 9.8
Employed at Home 69 2.3
Disabled due to MS 697 23.5
Retired 251 8.5
Homemaker 190 6.4
Unemployed 142 4.8
Student 30 1.0
Workers’ compensation 3 0.1
Positive smoking status: 517 17.4
SD, Standard Deviation.
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18 to 78 years). The sample was predominantly Caucasian
and female, and 55.7% were in the labor force, working
full or part time. The prevalence of smoking in this enrolled
sample was 17.4%; however, those who were disabled
due to MS or were unemployed for other reasons had
significantly higher rates of smoking than those who
were employed or retired.
Disease characteristics: duration, activity, symptoms and
disability status
Disease characteristics are detailed in Table 4. While the
mean time since first symptoms was 11.5 years, the median
time was 9.3 years with a range of less than one month to
60 years. The mean age at first symptoms was 37.5 years ±
10.2 years. The mean time since diagnosis was 9.5 years with
a median time of 7.4 years and a range of less than one year
to 47 years. More than 80% reported they were diagnosed
by physician assessment accompanied by magnetic reson-
ance imaging (MRI). About 75% were being treated by an
MS specialist neurologist. Nearly three-quarters of the en-
rolled sample were judged to have relapsing-remitting MS
based on their responses to pre-defined questions.
Disability level as measured with the Self-Assessed
Kurtzke was a median of 3.5 with an Inter-Quartile Range
of 0.0 to 5.5 and a mean of 3.2 (range: 0 to 8.5).About half of the participants reported having no
relapses in the year prior to enrollment. When asked
about physician-confirmed relapses, 17.2% reported one
confirmed relapse in the prior year while 6.3% reported two
confirmed relapses. The percentage of subjects reporting
one and two relapses irrespective of physician confirmation
were 22.0% and 10.6%, respectively. MRI was reported
in conjunction with symptoms of relapses by 18.8%,
and 21.7% received corticosteroid treatment in the year
prior to enrollment.
When asked about first MS symptoms and additional
symptoms they had experienced, participants reported
that many of them had persisted and were present at
study enrollment. The most commonly reported symp-
toms at the time of enrollment were fatigue (74.7%),
impaired coordination or balance (61.8%) and numbness
and tingling (61.2%).
As a requirement of study enrollment everyone was
continuing or initiating treatment with a DMT. There
were no significant differences in gender, race or current
symptoms across the DMTgroups.
Disease characteristics: psychosocial parameters
Table 5 presents the baseline psychosocial parameters.
The mean baseline scores on the Physical and Mental
Component Scores of the SF-12.v2® were below the 50th
percentiles compared to the US population [14]. These
component scores reflected the respective subscale scores:
the lowest mean scores and poorest quality of life assess-
ment were found on Physical Function (mean and standard
deviation [SD]: 40.9 ± 13.2) and Role Physical (mean and
SD: 41.2 ± 11.9) subscales while the highest scores came on
Bodily Pain (mean and SD: 46.6 ± 12.1) and Mental Health
(mean and SD: 47.4 ± 10.7) subscales.
The mean FSS score at baseline was 38.1 points, and
56.4% of participants met the criteria for severe fatigue
with mean baseline scores of 36 points or more.
Overall, 55.2% of participants screened positively for
major depression with scores of ≥ 3 points on the first
two questions of the PHQ-9. The mean baseline score
for the full nine items for all participants was 6.6
points on a range of 0 to 27 suggesting mildly severe
depression.
Of those who were employed and responded to the
WPAI-GH, 1055 reported missing 3.8% of their normal
work hours due to their MS in the past 7 days (absenteeism).
Additionally, 14.4% reported that while working they
were limited in the amount or kind of work they could do
(presenteeism). Combining the two forms of work prod-
uctivity loss showed that there was an overall productivity
loss of 15.8% over the past 7 days. There was a 35.0%
impairment due to MS in regular non-employment activ-
ities such as work around the house, shopping, childcare,
exercising or studying.
Table 4 Baseline disease characteristics of prevalent MS patients
Characteristic Mean SD
Time since first symptoms (years) 11.5 9.5
Time since diagnosis (years) 9.5 8.3
Characteristic n %
Disease course:a
Relapsing-remitting 2136 72.2
Secondary progressive 351 11.9
Primary progressive 437 14.8
Progressive-relapsing 26 0.9
Clinically Isolated Syndrome 8 0.3
Number of patient-reported relapses (not physician confirmed) in past year:
0 1455 49.1
1 652 22.0
2 314 10.6
3 130 4.4
4 52 1.8
>4 110 3.7
Uncertain 253 8.5
Current patient-reported symptoms:b
Fatigue 2215 74.7
Impaired coordination or balance 1834 61.8
Numbness and tingling 1814 61.2
Problems with thinking or memory 1599 53.9
Decreased strength in arms or legs 1548 52.2
Difficulty walking or moving legs 1442 48.6
Bladder problems 1350 45.5
Spasticity 1262 42.5
Pain 895 30.2
Visual symptoms 889 30.0
Bowel problems 774 26.1
Sexual dysfunction 734 24.7
Difficulty with speech or swallowing 637 21.5
Difficulty moving arms or hands 621 20.9
Tremor 527 17.8
Otherc 239 8.1
Disease-modifying therapy:
GA 1475 49.7
IFNβ-1a IM 604 20.4
IFNβ-1a SC 470 15.8
IFNβ-1b 417 14.1
SD, Standard Deviation; GA, Glaitramer acetate; IFN, Interferon; IM, Intramuscular; SC, Subcutaneous.
aDerived from responses to questions about confirmed relapses, onset of initial symptoms, and MS status relative to six months ago; 8 subjects did not
have required information. bMultiple responses were allowed; cMost commonly: Severe headaches/migraines, vertigo/dizziness, ringing in the ears, hearing
loss, seizures.
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Table 5 Baseline psychosocial characteristics of prevalent
MS patients
Characteristic Mean SD
Health-related quality of life component scores:a
Physical component score 42.6 11.8
Mental component score 46.9 11.2
Fatigue:b
FSS score 38.1 15.8
Depression:c
PHQ-9 score 6.6 5.7
Work productivity & activity impairment:d
Absenteeism (%) 3.8 14.9
Presenteeism (%) 14.4 20.4
Overall productivity loss (%) 15.8 22.1
Usual activity impairment (%) 35.0 30.8
SD, Standard Deviation.
aWare, JE et al. SF-12® Health Survey [14].
bKrupp LB et al. The Fatigue Severity Scale (FSS) [16].
cKroenke K et al. The Patient Health Question, 9 items (PHQ-9) [17,18].
dReilly MC, et al. Work Productivity and Activity Impairment-General
Health (WPAI-GH) [15].
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The TOP MS Study was designed to provide a patient-
focused assessment of the effect varying levels of DMT
compliance could have on MS-related disease outcomes.
The enrolled sample appeared to be representative of the
entire sample of MS patients available for recruitment from
the three US specialty pharmacies.
The database produced from the study is unique in
capturing DMT compliance from DMT shipment data
and does not rely solely on patient self-reports. Concord-
ance of self-reports and other measures of drug compliance
have been shown to vary widely, and self-reported com-
pliance is often significantly overestimated due to patients’
desires to provide socially acceptable responses [20-22].
Bruce et al. recently conducted a longitudinal study to
compare compliance outcomes for patients with MS
using retrospective self-reports, adherence diaries, and
an electronic monitoring device that captured time and
date of needle disposals [22]. While all measures of compli-
ance were correlated, patients reported better compliance
than was shown in diaries or devices. These authors con-
cluded that patient self-reports alone would underestimate
poor DMT compliance [22]. A somewhat more objective
measure of compliance than self-reports, the use of pre-
scription refill data to calculate MPR, had been used in
retrospective claims database research in MS [7]. The use
of prescription refill data reported as shipment data from
pharmacies is expected to provide a more accurate esti-
mate of compliance than self-reports for TOP MS.
The health outcomes for TOP MS are self-reported by
patients. Such self-reported surveys can provide reliablepatient-derived disability and clinical data as well as
assessments of health-related quality of life [23,24]. In-
vestigations comparing electronically collected patient-
reported outcomes to conventional pencil-and-paper
collection have concluded that data collected electronically
are valid and of comparable quality [24,25].
Key clinical characteristics suggest that the TOP MS sam-
ple is representative of other community-based prevalence
samples of MS patients. Although somewhat younger
at a mean age of 49.0 years compared to the NARCOMS
Registry 2008 Spring sample with a mean age of 53.4 years,
the years from diagnosis were correspondingly less for the
TOP MS sample at a mean of 9.5 years relative to the
NARCOMS sample at 14.8 years. Both samples were pre-
dominantly Caucasian and female [5]. The Clinformatics™
for Data Mart sample from 2006 to 2010 was also more
than 80% female but had a somewhat lower mean age of
45.2 years [7].
Compared to large observational studies of MS such
as the Sonya Slifka Longitudinal Multiple Sclerosis
Study in the US which looked at natural history of MS
and The Global Adherence Project (GAP) conducted
in twenty-two other countries, TOP MS had comparable
proportions of females, a lower proportion with no relapses
in the year prior to enrollment but similar proportions
of participants reporting one or two relapses in that
time frame [26,27]. Like the Slifka sample, the TOP MS
sample reported fatigue, and difficulty walking as the
most common current symptoms. More than half of
the Slifka sample had a disability status in the first
three levels of the Disease Steps, which was consistent
with the TOP MS sample where the median disability
scale score (EDSS) was 3.5 [26].
Limitations
TOP MS is a prospective observational study that poses
some methodological limitations as recently discussed by
Marrie [28]. Lack of randomization is an inherent feature
of observational studies, which can be, in part, addressed
by increasing sample size. TOP MS represents the largest
study of treated MS patients to be recruited for a study of
compliance in the US. Observational studies sometimes
lack standardized data collection, but TOP MS was de-
signed around an electronic database that assured each
patient responded to the same questions at each mod-
ule and over time. Other methodological issues include
possible selection bias and non-response bias. The rep-
resentativeness of the enrolled TOP MS sample com-
pared to the eligible participants from the pharmacies
suggests that there has been limited selection bias within
the subject pool. Non-response to the baseline surveys
was 5.9% (185/3151) which compares favorably to a recent
report by Jongen et al. who reported that of a sample of
163 MS patients who enrolled in a monthly electronic
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Nonresponse will be examined more completely when the
full TOP MS is reported.
Conclusions
The TOP MS Study provides a unique opportunity to
examine compliance with drug use in an MS sample that
appears to be representative of DMT users in the US. Due
to the frequency and depth of data collection, the TOP MS
database contains a wealth of information. In this report,
we describe the study methodology and data collected at
baseline. In future reports we will address the primary
outcome of the study including longitudinal data showing
change over time, outcomes and predictive variables.
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